Latest news

The Adalvo team have certainly been busy bees this year, driven by their passion for relentless commitment to customers and business partners. Adalvo has been a true success story...

Adalvo is happy to announce that in addition to our earlier reported studies we successfully closed our last bioequivalence trial that was conducted in steady state dosing.

Alvotech and Teva bring together highly complementary capabilities to secure a leading position in the U.S. biosimilar market. The collaboration is one of the broadest partnerships within the U.S. biosimilar...

Adalvo today announced that it has entered into partnership with AmbioPharm, a US-based pharmaceutical company, for an exclusive collaboration on the co-development and licensing for the commercialization of several complex...

Adalvo is delighted to announce successful Fed and Fast Pivotal BE outcome of its Solifenacin + Tamsulosin development which demonstrates Adalvo's ability to continuously offer first-to-market opportunities to its valued...

Adalvo today announces that it has submitted filings for generic dossier applications with the European Medicines Agency, seeking approval to market an Icatibant pre-filled syringe. Based on available information, Adalvo...

New commercialization agreement in Latin America announced with a large, multinational pharmaceutical firm.

Adalvo, the new B2B company as part of the Alvogen and Alvotech family, have worked with Lotus pharmaceuticals in Asia to announce 10 new strategic partnership agreements in 2020 with...

Global pharmaceutical companies Alvogen and Alvotech have introduced a new corporate identity for its B2B operations – called Adalvo – following rapid growth in this area of business in the...

We are living through a very challenging time. The Coronavirus spread is causing changes in everyday life and we are constantly monitoring the situation here at Adalvo

Alvogen today announced that it has submitted generic dossier applications for Pazopanib tablets.

Alvotech Hf and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced that Alvotech Hf and DKSH have entered into an exclusive license partnership for...

This February the Adalvo team got together in Zurich, Switzerland for a Kick Off meeting.

Adalvo is delighted to partner with JSC Olainfarm to launch a new product within the urology segment which is targeted to be the 1st to market opportunity in 17 countries....

At Adalvo, we are committed to advancing the treatment of central nervous system (CNS) disorders through the development and commercialization of differentiated and high-quality pharmaceutical products. Our CNS/Neurology portfolio addresses...

At Adalvo, we are dedicated to providing advanced and effective solutions for managing pain. Our pain portfolio includes a range of high-quality, differentiated products designed to address various pain conditions...

At Adalvo, we are committed to advancing the treatment options available for patients suffering from rheumatological conditions. Our robust portfolio addresses a wide range of autoimmune and inflammatory diseases, providing...

Adalvo's Urology Dossiers feature a range of essential products designed to address various urological conditions, including urinary incontinence, overactive bladder, and more. With a focus on quality, efficacy, and patient-centric...

Adalvo's rare disease portfolio encompasses a diverse array of treatments designed to target several rare diseases. Each dossier within our portfolio is developed to improve the quality of life and...

At Adalvo, we prioritize women's health by offering a comprehensive range of products designed to address various health needs throughout every stage of a woman's life. From reproductive health to...

At Adalvo, we are committed to advancing healthcare solutions to combat infectious diseases and enhance patient outcomes worldwide. Explore our diverse portfolio of anti-infections dossiers below.